Malaria vaccine - Crucell

Drug Profile

Malaria vaccine - Crucell

Alternative Names: Ad35-CS

Latest Information Update: 09 Sep 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Crucell
  • Developer Crucell; National Institute of Allergy and Infectious Diseases; PATH
  • Class Antimalarials; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Malaria

Most Recent Events

  • 01 Jun 2014 The National Institute of Allergy and Infectious Diseases completes a phase I trial in Malaria (in volunteers) in USA (NCT00371189)
  • 06 Sep 2013 Isconova is now called Novavax AB
  • 22 Aug 2013 Isconova has been acquired by Novavax
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top